244
Participants
Start Date
August 6, 2012
Primary Completion Date
October 10, 2013
Study Completion Date
January 15, 2019
GSK1265744 10 mg
GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
GSK1265744 30 mg
GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
GSK1265744 60 mg
GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Efavirenz 600 mg
Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
Rilpivirine 25 mg
Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
Placebo
Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
GSK Investigational Site, New York
GSK Investigational Site, Valhalla
GSK Investigational Site, Albany
GSK Investigational Site, Buffalo
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Annandale
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Charleston
GSK Investigational Site, Atlanta
GSK Investigational Site, Augusta
GSK Investigational Site, Macon
GSK Investigational Site, Savannah
GSK Investigational Site, Orlando
GSK Investigational Site, Miami
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Oakland Park
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, West Palm Beach
GSK Investigational Site, Ft. Pierce
GSK Investigational Site, Birmingham
GSK Investigational Site, Indianapolis
GSK Investigational Site, Minneapolis
GSK Investigational Site, Kansas City
GSK Investigational Site, Omaha
GSK Investigational Site, Little Rock
GSK Investigational Site, Dallas
GSK Investigational Site, Austin
GSK Investigational Site, Denver
GSK Investigational Site, Phoenix
GSK Investigational Site, Las Vegas
GSK Investigational Site, Los Angeles
GSK Investigational Site, Beverly Hills
GSK Investigational Site, Long Beach
GSK Investigational Site, Bakersfield
GSK Investigational Site, San Francisco
GSK Investigational Site, Boston
GSK Investigational Site, Hillsborough
GSK Investigational Site, Neptune City
GSK Investigational Site, Providence
GSK Investigational Site, Vancouver
GSK Investigational Site, Vancouver
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Montreal
GSK Investigational Site, Montreal
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY